替罗非班对急性心梗患者急诊PCI中冠脉内血栓的影响  

Effect of Tirofiban on Intra-coronary Thrombosis in Patients with STEMI During Emergency PCI

作　　者：张怀勇[1] 于波[2] 

机构地区：[1]黑龙江省森工总医院,黑龙江哈尔滨150040 [2]哈尔滨医科大学附属第二医院,黑龙江哈尔滨150086

出　　处：《现代生物医学进展》2008年第9期1702-1703,共2页Progress in Modern Biomedicine

基　　金：国家"863"基金资助项目(2004AA2Z3761)

摘　　要：目的:探讨替罗非班对ST段抬高急性心肌梗死患者直接经皮冠状动脉内介入治疗(PCI)中冠状动脉内血栓的影响。方法:79例患者,随机分为试验组(替罗非班+PCI,34例)和对照组(直接PCI,45例)。观察住院期间主要心血管事件(MACE)发生率,冠状动脉内血栓和使用替罗非班的不良反应。结果:与对照组相比,试验组于术前应用替罗非班使PCI术前梗死相关血管(IRA)内血栓存在比例明显降低(P<0.05);试验组出血发生率较对照组有增多趋势(P>0.05)。结论:早期使用血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班,可以明显减少STEMI梗死相关血管内血栓的发生率。Objective： To explore the effect of tirofiban on intra-coronary thrombosis in patients with the ST-segment elevation myocardial infarction（STEMI） during emergency pereutaneous coronary intervention（PCI）. Methods： 79 patients with STEMI were randomly divided into two groups the experimental group （n=34）, treated with tirofiban before PCI; the control group（n=45 ）, treated with PCI only.During hospitalization,the inpatients were observed in the major adverse cardiovascular events （MACE） rate, intra-coronary thrombosis incidence and adverse reaction of tirofiban, Results Compared with the control group,the percentage of thrombosis in the infarction-related arteries（IRA） obviously decreased（P〈0.05 ）. The hemorrhage incidence in the experimental group was higher than that in the control group（P〉0.05 ）. Conclusion： In the early stage using tirofiban, the platelet glycoprotein receptor antagonist, can reduce incidence of thrombosis in the IRA of patients with STEMI.

关 键 词：替罗非班 心肌梗死 冠状动脉 血栓 介入治疗 

分 类 号：R542.22[医药卫生—心血管疾病]